- cafead   May 07, 2024 at 06:42: PM
via With $1.1 billion cash on Madrigal Pharmaceuticals’ balance sheet, CEO Bill Sibold believes the company can “fully resource” the launch of Rezdiffra, the first FDA-approved therapy for fatty liver disease.
article source
article source